Adaptimmune Therapeutics plc
ADAP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $13,677 | $7,285 | $3,222 | $40,901 |
| % Growth | 87.7% | 126.1% | -92.1% | – |
| Cost of Goods Sold | $2,501 | $879 | $0 | $0 |
| Gross Profit | $11,176 | $6,406 | $3,222 | $40,901 |
| % Margin | 81.7% | 87.9% | 100% | 100% |
| R&D Expenses | $22,979 | $28,857 | $39,101 | $34,304 |
| G&A Expenses | $17,914 | $21,260 | $20,713 | $21,277 |
| SG&A Expenses | $17,914 | $23,282 | $21,219 | $21,277 |
| Sales & Mktg Exp. | $0 | $360 | $506 | $0 |
| Other Operating Expenses | $571 | $0 | $16,421 | $0 |
| Operating Expenses | $41,464 | $52,139 | $76,741 | $55,581 |
| Operating Income | -$30,288 | -$45,733 | -$73,519 | -$14,680 |
| % Margin | -221.5% | -627.8% | -2,281.8% | -35.9% |
| Other Income/Exp. Net | $560 | -$1,276 | $3,301 | -$2,106 |
| Pre-Tax Income | -$29,728 | -$47,009 | -$70,218 | -$16,786 |
| Tax Expense | $612 | $575 | -$1,283 | $831 |
| Net Income | -$30,340 | -$47,584 | -$74,215 | -$17,617 |
| % Margin | -221.8% | -653.2% | -2,303.4% | -43.1% |
| EPS | -0.12 | -0.19 | -0.29 | -0.069 |
| % Growth | 36.8% | 34.5% | -320.3% | – |
| EPS Diluted | -0.12 | -0.19 | -0.29 | -0.069 |
| Weighted Avg Shares Out | 264,087 | 257,027 | 255,942 | 255,769 |
| Weighted Avg Shares Out Dil | 264,087 | 257,027 | 255,942 | 255,769 |
| Supplemental Information | – | – | – | – |
| Interest Income | $233 | $910 | $1,779 | $2,096 |
| Interest Expense | $962 | $1,881 | $1,713 | $1,109 |
| Depreciation & Amortization | $2,509 | $2,466 | $2,835 | $2,818 |
| EBITDA | -$26,257 | -$42,662 | -$67,974 | -$12,859 |
| % Margin | -192% | -585.6% | -2,109.7% | -31.4% |